120 related articles for article (PubMed ID: 7826031)
1. Role of EBV and Ig/myc translocation in Burkitt lymphoma.
Klein G
Antibiot Chemother (1971); 1994; 46():110-6. PubMed ID: 7826031
[No Abstract] [Full Text] [Related]
2. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
Doyle MG; Crawford DH
Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878
[TBL] [Abstract][Full Text] [Related]
3. EBV and Burkitt's lymphoma.
Rossi G; Bonetti F
N Engl J Med; 2004 Jun; 350(25):2621; author reply 2621. PubMed ID: 15201422
[No Abstract] [Full Text] [Related]
4. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.
Chen F; Zou JZ; di Renzo L; Winberg G; Hu LF; Klein E; Klein G; Ernberg I
J Virol; 1995 Jun; 69(6):3752-8. PubMed ID: 7745723
[TBL] [Abstract][Full Text] [Related]
5. Integration of a short Epstein-Barr virus DNA fragment in a B95-8 virus converted Burkitt lymphoma line expressing Epstein-Barr nuclear antigens EBNA2 and EBNA5.
Trivedi P; Cuomo L; de Campos-Lima PO; Imreh MP; Kvarnung K; Klein G; Masucci MG
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1393-8. PubMed ID: 8393080
[TBL] [Abstract][Full Text] [Related]
6. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.
Sugiura M; Imai S; Tokunaga M; Koizumi S; Uchizawa M; Okamoto K; Osato T
Br J Cancer; 1996 Aug; 74(4):625-31. PubMed ID: 8761381
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies.
Robertson KD; Barletta J; Samid D; Ambinder RF
Curr Top Microbiol Immunol; 1995; 194():145-54. PubMed ID: 7534666
[No Abstract] [Full Text] [Related]
9. Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells.
Wolf J; Pawlita M; Klevenz B; Frech B; Freese UK; Müller-Lantzsch N; Diehl V; zur Hausen H
Int J Cancer; 1993 Feb; 53(4):621-7. PubMed ID: 8382194
[TBL] [Abstract][Full Text] [Related]
10. EBNA2 and c-myc in B cell immortalization by Epstein-Barr virus and in the pathogenesis of Burkitt's lymphoma.
Zimber-Strobl U; Strobl L; Höfelmayr H; Kempkes B; Staege MS; Laux G; Christoph B; Polack A; Bornkamm GW
Curr Top Microbiol Immunol; 1999; 246():315-20; discussion 321. PubMed ID: 10396071
[No Abstract] [Full Text] [Related]
11. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
Bieging KT; Amick AC; Longnecker R
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus and Burkitt lymphoma.
Brady G; Macarthur GJ; Farrell PJ
Postgrad Med J; 2008 Jul; 84(993):372-7. PubMed ID: 18716017
[TBL] [Abstract][Full Text] [Related]
14. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.
Gruhne B; Sompallae R; Masucci MG
Oncogene; 2009 Nov; 28(45):3997-4008. PubMed ID: 19718051
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus in lymphoproliferative processes: an update for the diagnostic pathologist.
Ng SB; Khoury JD
Adv Anat Pathol; 2009 Jan; 16(1):40-55. PubMed ID: 19098466
[TBL] [Abstract][Full Text] [Related]
17. Expression of Epstein-Barr virus-encoded latent membrane protein 1 in nonendemic Burkitt's lymphomas.
Carbone A; Gloghini A; Zagonel V; Tirelli U
Blood; 1996 Feb; 87(3):1202-4. PubMed ID: 8562951
[No Abstract] [Full Text] [Related]
18. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
Aguirre AJ; Robertson ES
J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
[TBL] [Abstract][Full Text] [Related]
19. Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line.
Lacy J; Summers WP; Watson M; Glazer PM; Summers WC
Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5838-42. PubMed ID: 3039510
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus and the immune system. Hide and seek.
Cohen JI
JAMA; 1997 Aug; 278(6):510-3. PubMed ID: 9256227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
